Drugs / GT101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06077903 | Jul 2021 → Dec 2025 | — | Grit Biotechnology | Terminated | No outcome recorded Stop: Business |
| Phase 11 trial | ||||||
| Phase 1 | NCT05430373 | May 2022 → Sep 2025 overdue | — | Grit Biotechnology | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06241781 | Apr 2024 → Jan 2027 expected | — | Grit Biotechnology | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-05-29 | Grit Biotechnology | Results 沙砾生物在ASCO 2025公布多项TIL细胞疗法临床进展 gritbio.com ↗
在一项针对GT101的I期临床试验中，沙砾生物开发的TIL疗法在11例复发性或转移性宫颈癌患者中展现出可控的安全性和良好的临床疗效。 |
| 2024-05-24 | Grit Biotechnology | Results 沙砾生物将在ASCO 2024展示细胞治疗领域最新研究成果 (1) GT101 gritbio.com ↗
沙砾生物此次展示了TIL注射液GT101的I期临床研究中的安全性和临床疗效数据。 |
| 2022-11-11 | Grit Biotechnology | Regulatory Grit Bio （沙砾生物） Receives NMPA’s IND Approval for GT101 gritbio.com ↗
April 22, 2022, Investigational New Drug (IND) Application of Grit Bio’s GT101 has been approved by National Medical Products Administration (NMPA) (acceptance number: CXSL2200061). |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-29 | Grit Biotechnology | 沙砾生物在ASCO 2025公布多项TIL细胞疗法临床进展 gritbio.com ↗ |
| 2024-08-08 | Grit Biotechnology | 沙砾生物TIL产品“GT101”关键II期临床试验——全国研究者会顺利召开 gritbio.com ↗ |
| 2024-05-24 | Grit Biotechnology | 沙砾生物将在ASCO 2024展示细胞治疗领域最新研究成果 (1) GT101 gritbio.com ↗ |
| 2024-04-01 | Grit Biotechnology | 沙砾生物TIL产品“GT101”关键II期临床试验启动会顺利召开 gritbio.com ↗ |
| 2022-11-11 | Grit Biotechnology | Grit Bio （沙砾生物） Dosed First Patient in GT101 Phase 1 Trial gritbio.com ↗ |
| 2022-11-11 | Grit Biotechnology | Grit Bio （沙砾生物） Receives NMPA’s IND Approval for GT101 gritbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06077903 ↗ |
| Modality | Cell therapy | “Autologous tumor infiltrating lymphocyte injection” NCT05430373 ↗ |